IL152507A0 - Methods and compositions for impairing multiplication of hiv-1 - Google Patents

Methods and compositions for impairing multiplication of hiv-1

Info

Publication number
IL152507A0
IL152507A0 IL15250701A IL15250701A IL152507A0 IL 152507 A0 IL152507 A0 IL 152507A0 IL 15250701 A IL15250701 A IL 15250701A IL 15250701 A IL15250701 A IL 15250701A IL 152507 A0 IL152507 A0 IL 152507A0
Authority
IL
Israel
Prior art keywords
sub
asn
pro
variants
asp
Prior art date
Application number
IL15250701A
Other languages
English (en)
Original Assignee
Thymon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thymon Llc filed Critical Thymon Llc
Publication of IL152507A0 publication Critical patent/IL152507A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
IL15250701A 2000-04-28 2001-04-20 Methods and compositions for impairing multiplication of hiv-1 IL152507A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/561,366 US6399067B1 (en) 2000-04-28 2000-04-28 Methods and compositions for impairing multiplication of HIV-1
PCT/US2001/013031 WO2001082944A1 (en) 2000-04-28 2001-04-20 Methods and compositions for impairing multiplication of hiv-1

Publications (1)

Publication Number Publication Date
IL152507A0 true IL152507A0 (en) 2003-05-29

Family

ID=24241644

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15250701A IL152507A0 (en) 2000-04-28 2001-04-20 Methods and compositions for impairing multiplication of hiv-1

Country Status (19)

Country Link
US (4) US6399067B1 (no)
EP (1) EP1278534B1 (no)
JP (1) JP4282934B2 (no)
CN (1) CN1426306A (no)
AT (1) ATE350049T1 (no)
AU (2) AU2001253762B9 (no)
CA (1) CA2406746A1 (no)
DE (1) DE60125751T2 (no)
DK (1) DK1278534T3 (no)
ES (1) ES2278741T3 (no)
IL (1) IL152507A0 (no)
MX (1) MXPA02010632A (no)
NO (1) NO20025153L (no)
NZ (1) NZ522824A (no)
PL (1) PL363071A1 (no)
PT (1) PT1278534E (no)
RU (1) RU2275379C2 (no)
WO (1) WO2001082944A1 (no)
ZA (1) ZA200208632B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
CA2525640C (en) * 2003-04-11 2014-10-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Multiple antigenic peptide assay for detection of hiv or siv type retroviruses
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
WO2006088739A1 (en) * 2005-02-15 2006-08-24 Thymon, L.L.C. Assays for detecting the tat protein in hiv-1 infection
EP1851247A2 (en) * 2005-02-15 2007-11-07 Thymon L.L.C. Methods and compositions for impairing multiplication of hiv-1
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
CA2660830A1 (en) * 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
US20110027315A1 (en) * 2007-09-07 2011-02-03 Allen Harmsen Protein cages and their uses
CA2755897C (en) 2009-03-23 2020-01-28 Nanirx, Inc. Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
US8187611B2 (en) * 2009-10-29 2012-05-29 Albert Einstein College Of Medicine Of Yeshiva University Anti-peptide antibodies that cross react with protective antigen of Bacillus anthracis and uses thereof
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
EP2511295A1 (en) * 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US601977A (en) * 1898-04-05 Bicycle-canopy
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US6001977A (en) * 1984-08-22 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5801056A (en) * 1985-05-24 1998-09-01 Dana-Farber Cancer Institute Nucleic acid encoding HIV-1 tat protein
US4735896A (en) * 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
PT83682B (en) 1985-11-06 1988-12-05 Smithkline Beckman Corp Process for the expression of an aids virus gene
CS256960B1 (en) * 1985-11-16 1988-04-15 Viktor Krchnak Peptides with properties of antigenic determinants and method of their production
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5306614A (en) * 1986-01-22 1994-04-26 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2)
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
US5476765A (en) * 1987-01-09 1995-12-19 United Biomedical, Inc. Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines
US5026635A (en) * 1987-05-19 1991-06-25 Du Pont Merck Pharmaceutical Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
US5110802A (en) 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
US5831034A (en) * 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5606026A (en) * 1988-03-25 1997-02-25 The Institute For Human Genetics And Biochemistry Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1
GB8808892D0 (en) 1988-04-15 1988-05-18 British Bio Technology Gene synthesis
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
AU658818B2 (en) 1989-12-21 1995-05-04 Johns Hopkins University School Of Medicine, The Method of delivering molecules into eukaryotic cells using tat protein conjugate
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP0511285A4 (en) 1990-01-18 1993-05-26 Us Commerce Vector with multiple target response elements affecting gene expression
GB9003010D0 (en) 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
GB9016973D0 (en) * 1990-08-02 1990-09-19 Medical Res Council Viral growth inhibition
CA2092075A1 (en) 1990-10-24 1992-04-25 Martin Sumner-Smith Peptide-based inhibitors of hiv replication
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
EP0571549A4 (en) 1991-02-14 1995-03-15 Jolla Cancer Res Found INNOVATIVE INTEGRIN SPECIFICITY FOR THE HIV-TAT PROTEIN.
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
EP0642582A1 (en) * 1992-05-22 1995-03-15 Dana Farber Cancer Institute Hybrid siv/hiv-1 viral vectors and monkey model for aids
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
WO1994015969A1 (en) * 1993-01-14 1994-07-21 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-hiv antibody and preparation thereof
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
CA2190972A1 (en) 1994-05-23 1995-11-30 Gideon Goldstein Compositions of transactivating proteins of human immunodeficiency virus
WO1998014587A1 (en) * 1996-10-04 1998-04-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEAL TH AND HUMAN SERVICES Inhibition of hiv replication using soluble tat peptide analogs
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
US20050245454A1 (en) 2005-11-03
RU2275379C2 (ru) 2006-04-27
CA2406746A1 (en) 2001-11-08
AU5376201A (en) 2001-11-12
EP1278534B1 (en) 2007-01-03
CN1426306A (zh) 2003-06-25
MXPA02010632A (es) 2003-03-10
AU2001253762B9 (en) 2005-11-17
WO2001082944A1 (en) 2001-11-08
JP2004514406A (ja) 2004-05-20
AU2001253762B2 (en) 2005-09-22
DE60125751T2 (de) 2007-10-31
US20020192232A1 (en) 2002-12-19
US20030180326A1 (en) 2003-09-25
US6399067B1 (en) 2002-06-04
EP1278534A1 (en) 2003-01-29
DK1278534T3 (da) 2007-05-14
PL363071A1 (en) 2004-11-15
EP1278534A4 (en) 2004-09-15
PT1278534E (pt) 2007-02-28
ES2278741T3 (es) 2007-08-16
ATE350049T1 (de) 2007-01-15
ZA200208632B (en) 2004-02-12
US6524582B2 (en) 2003-02-25
NZ522824A (en) 2004-09-24
DE60125751D1 (de) 2007-02-15
JP4282934B2 (ja) 2009-06-24
NO20025153L (no) 2002-12-16
NO20025153D0 (no) 2002-10-25

Similar Documents

Publication Publication Date Title
AU5376201A (en) Methods and compositions for impairing multiplication of hiv-1
EP0994724A4 (en) METHODS AND COMPOSITIONS TO PREVENT THE REPRODUCTION OF HIV-1
US5840313A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
NZ333999A (en) GnRH-leukotoxin chimeric proteins for use in vaccines
RU96102594A (ru) Тандемные синтетические hiv-1 пептиды
JP2002206000A5 (no)
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
CA2181590A1 (en) Peptomers with enhanced immunogenicity
US5346989A (en) Peptides for use in induction of T cell activation against HIV-1
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
US5622933A (en) Multiple branch peptide constructions for use against HIV
WO2003059953B1 (en) Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
EP1250358B1 (en) Therapeutic peptides
CA2338886A1 (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
WO2003022879B1 (en) Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them
SG44828A1 (en) New soluble non-cleavable gp160 variant of hybrid form
CA2160696C (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
AU6393990A (en) Hiv related peptides
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2002051865A3 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
HK1028065A1 (en) Peptides for the detection of hiv-1-group o.
Syennerholm et al. Vahlne et al.